Objective: Clinical trials generally allocate patients to equal-sized treatment groups. The authors propose that it may be more efficient to allocate unequal proportions of the total sample size to treatments when more than two treatments are being compared.
Method: This proposal is illustrated with two examples. One involved a comparison of three treatments and used a dichotomous categorical outcome. The other involved comparison of three treatments and used a continuous measure.
Results: In both examples, a considerable increase in efficiency was realized by reducing the number of patients assigned to the placebo cell.
Conclusions: Unequal allocation of patients to treatments should be considered when more than two groups are compared.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/ajp.155.10.1446 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic Literature Review of Access Pathways to Drugs for Patients with Rare Diseases.
Appl Health Econ Health Policy
December 2024
Centre for Health Economics Research and Evaluation, University of Technology Sydney, Level 5, Building 20, 100 Broadway, Chippendale, Sydney, NSW, 2008, Australia.
Objective: This article reviews the assessment pathways that have been implemented worldwide to facilitate access to drugs for patients with rare diseases.
Methods: The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines were used to conduct a systematic literature review. The Ovid (Embase/MEDLINE), Cochrane, Web of Science, Econlit, National Institute of Health Research, Centre for Reviews and Dissemination, and International Network of Agencies for Health Technology Assessment databases were searched.
Factors affecting intensive care length of stay in critically ill pediatric patients with burn injuries.
Pediatr Surg Int
December 2024
Department of Pediatric Critical Care, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.
Background: Burns in children are often complex injuries, leading to prolonged length of stay (LOS) and significant morbidity. LOS in pediatric intensive care units (PICUs) is a key measure for evaluating illness severity, clinical outcomes, and quality of care. Accurate prediction of LOS is vital for improving care planning and resource allocation.
View Article and Find Full Text PDFBackground: To analyse the epidemiological characteristics of orthopaedic trauma patients and thereby optimize healthcare resource allocation and improve treatment efficiency.
Materials And Methods: Relying on the hospital information system (HIS) database, we retrospectively analysed the epidemiological characteristics of orthopaedic trauma inpatients in our hospital between 2013 and 2022, including patient demographic information, causes of injury, location of injury and hospitalization costs.
Results: The median age of the patients was 36 (26-47) years old; the age stratification of the patients was highest in the proportion of patients aged 40-50 years old (29.
The Financial Burden of Localized and Metastatic Bladder Cancer.
Eur Urol
December 2024
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background And Objective: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. Understanding these financial implications is crucial for effective resource allocation and optimization of treatment cost effectiveness. Here, we aim to systematically review and analyze the financial burden of BCa from the health care and patient perspectives.
View Article and Find Full Text PDFUrinary Circular RNA Panels to Detect HBV-Related Hepatocellular Carcinoma: A Multicenter, Large-Scale, Case-Control Study.
J Natl Compr Canc Netw
December 2024
1Department of Hepatology, The Fifth People's Hospital of Ganzhou, Ganzhou, Jiangxi Province, China.
Purpose: More than 60% of patients with hepatocellular carcinoma (HCC) do not receive curative therapeutics due to late clinical manifestations and diagnosis. The 5-year survival rate for advanced HCC is approximately 2%. However, curative therapies for HCC detected early can improve the 5-year survival rate to >70%.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!